FDA.reportPublic FDA data

Trijardy XR 5 MG / 2.5 MG / 1000 MG 24HR Extended Release Oral Tablet

RxCUI
2359358
RxNorm name
Trijardy XR 5 MG / 2.5 MG / 1000 MG 24HR Extended Release Oral Tablet
Display name
Trijardy XR 5 MG / 2.5 MG / 1000 MG 24HR Extended Release Oral Tablet
Full name
Trijardy XR 5 MG / 2.5 MG / 1000 MG 24HR Extended Release Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:03

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Trijardy XREMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDEBoehringer Ingelheim Pharmaceuticals, Inc.71873567-9594-452a-bb92-34a129adecac2026-01-30Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2359358

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
71873567-9594-452a-bb92-34a129adecacTrijardy XR 5 MG / 2.5 MG / 1000 MG 24HR Extended Release Oral TabletPSN10These highlights do not include all the information needed to use TRIJARDY XR safely and effectively. See full prescribing information for TRIJARDY XR. TRIJARDY ® XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 202020260130
71873567-9594-452a-bb92-34a129adecac24 HR empagliflozin 5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Trijardy]SBD10These highlights do not include all the information needed to use TRIJARDY XR safely and effectively. See full prescribing information for TRIJARDY XR. TRIJARDY ® XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 202020260130
71873567-9594-452a-bb92-34a129adecacTrijardy XR (empagliflozin 5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG) 24HR Extended Release Oral TabletSY10These highlights do not include all the information needed to use TRIJARDY XR safely and effectively. See full prescribing information for TRIJARDY XR. TRIJARDY ® XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 202020260130